Circulating Long-Non Coding RNA RP11-445H22.4 as a Diagnostic and Prognostic Biomarker of Breast Cancer | ||
| Zagazig University Medical Journal | ||
| Article 10, Volume 30, Issue 9, December 2024, Pages 4383-4390 PDF (1010.01 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2024.314097.3531 | ||
| Authors | ||
| Lamiaa M. Kamel* 1; Ebtehag Helmy Hassan2; Sara Mohammed Ibrahim3; Mohamed I.Abdelhamid4; Abdallah S. Abdelazem5; Abeer A. Fikry6 | ||
| 1Clinical Pathology Department , ,Faculty of Medicine, Zagazig University, Zagazig ,Egypt | ||
| 2Clinical pathology Department, Faculty of medicine, Zagazig University, Zagazig, Egypt | ||
| 3Clinical Pathology Department , ,faculty of medicine,zagazig university,zagazig,Egypt | ||
| 4General Surgery Department, Faculty of Medicine, Zagazig university, Zagazig, Egypt | ||
| 5Medical Biochemistry Department , ,Faculty of Medicine, Suez University, Suez , Egypt | ||
| 6Clinical Pathology Department , Faculty of Medicine, Zagazig University, Zagazig, Egypt | ||
| Abstract | ||
| Background: The most frequent malignancy in women is breast cancer (BC). Biomarkers, like carbohydrate antigen (CA15-3) as well as carcino-embryonic antigen (CEA), remain of limited clinical value. Novel biomarkers are needed for early diagnosis. This study aimed at evaluating the role of circulating long non-coding RNA RP11-445H22.4 as a diagnostic marker of breast cancer and to assess its relation with prognostic characteristics of the disease. Methods: It was a case-control study conducted in Clinical Pathology and General Surgery Departments, Faculty of Human Medicine , Zagazig University. It involved 108 adult females: 36 females as healthy control, 36 newly diagnosed females with BC, and 36 females with benign breast lesions. Patients were diagnosed by mammography and biopsy. LncRNA RP11-445H22.4 was assessed in plasma by quantitative real-time polymerase chain reaction. Results: lncRNA RP11-445H22.4 was elevated among BC cases compared to controls as well as cases of benign breast lesions. The lncRNA RP11-445H22.4 revealed 95.9% sensitivity and 91.8% specificity for discriminating breast cancer vs. controls and benign breast lesions. CA15-3 had 77.8% sensitivity and 80.7% specificity. lncRNA RP11-445H22.4 showed 81.8% specificity versus 75.9% specificity for CA15-3 differentiating TNM stages ; I and II vs. III and IV. Conclusions: LncRNA RP11-445H22.4 was up-regulated in breast cancer cases compared to controls and cases with benign breast lesions, it exhibited greater sensitivity and specificity compared to traditional biomarkers. Level of LncRNA RP11-445H22.4 was related to ER, PR and Her2/neu in BC patients. Consequently, it could serve as a potential biomarker for breast cancer diagnosis and prognosis. | ||
| Keywords | ||
| Breast cancer; biomarker; Long non coding RNA RP11-445H22.4 | ||
|
Statistics Article View: 1,499 PDF Download: 95 |
||
